Comparison of Phoenix and VITEK 2 Extended-Spectrum-β-Lactamase Detection Tests for Analysis of Escherichia coli and Klebsiella Isolates with Well-Characterized β-Lactamases

ABSTRACT The VITEK 2 and Phoenix extended-spectrum β-lactamase (ESBL) detection systems, which comprise confirmatory tests and expert systems, were evaluated for their ability to discriminate between 102 well-characterized strains of ESBL-positive or -negative Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. At least 38 distinct ESBLs were included. The strains were chosen to include some known to cause false-positive and false-negative CLSI ESBL confirmatory test results. Therefore, enzyme characterizations, rather than CLSI tests, were the reference methods for the Phoenix and VITEK 2 evaluations. A third arm of the study was conducted with the Phoenix test using two normally inactive expert rules intended to enhance ESBL detection, in addition to using the currently available software. The Phoenix ESBL confirmatory test and unmodified expert system exhibited 96% sensitivity and 81% specificity for ESBL detection. Activation of the two additional rules increased sensitivity to 99% but reduced the specificity to 58%. The VITEK 2 ESBL confirmatory test exhibited 91% sensitivity, which was reduced to 89% sensitivity by its expert system, while its specificity was 85%. Many of the expert system interpretations of both instruments were helpful, but some were suboptimal. The VITEK 2 expert system was potentially more frustrating because it provided more inconclusive interpretations of the results. Considering the high degree of diagnostic difficulty posed by the strains, both ESBL confirmatory tests were highly sensitive. The expert systems of both instruments require modification to update and enhance their utility.

[1]  Kenneth S. Thomson,et al.  Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital , 2001, Journal of Clinical Microbiology.

[2]  Maurizio Sanguinetti,et al.  Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.

[3]  Harald Seifert,et al.  Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures , 2007, Journal of Clinical Microbiology.

[4]  John Quale,et al.  Emergence of KPC-Possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and Recommendations for Detection , 2005, Antimicrobial Agents and Chemotherapy.

[5]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[6]  D. Mack,et al.  Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. , 2003, Diagnostic microbiology and infectious disease.

[7]  P. Nordmann,et al.  Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. , 2002, Current pharmaceutical biotechnology.

[8]  D. Landman,et al.  Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter spp. from Brooklyn, New York , 2005, Antimicrobial Agents and Chemotherapy.

[9]  Armand Paauw,et al.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp , 2002, Journal of Clinical Microbiology.

[10]  Wonkeun Song,et al.  Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002 , 2006, Journal of Clinical Microbiology.

[11]  Neil Woodford,et al.  Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.

[12]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[13]  Maurizio Sanguinetti,et al.  Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates , 2006, Journal of Clinical Microbiology.

[14]  P. Bradford,et al.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Goering,et al.  Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. , 2003, The Journal of antimicrobial chemotherapy.

[16]  E. S. Moland,et al.  Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli, Klebsiella spp.,Enterobacter spp., Citrobacter freundii, andSerratia marcescens , 1999, Antimicrobial Agents and Chemotherapy.

[17]  K. Thomson Controversies about extended-spectrum and AmpC beta-lactamases. , 2001, Emerging infectious diseases.